Show simple item record

dc.contributor.authorNyendak, Melissa R.
dc.contributor.authorByung, Park
dc.contributor.authorNull, Megan D.
dc.contributor.authorBaseke, Joy
dc.contributor.authorSwarbrick, Gwendolyn
dc.contributor.authorMayanja-Kizza, Harriet
dc.contributor.authorNsereko, Mary
dc.contributor.authorJohnson, Denise F.
dc.contributor.authorGitta, Phineas
dc.contributor.authorOkwera, Alphonse
dc.contributor.authorGoldberg, Stefan
dc.contributor.authorBozeman, Lorna
dc.contributor.authorJohnson, John L.
dc.contributor.authorBoom, W. Henry
dc.date.accessioned2022-01-31T10:17:14Z
dc.date.available2022-01-31T10:17:14Z
dc.date.issued2013
dc.identifier.citationNyendak MR, Park B, Null MD, Baseke J, Swarbrick G, et al. (2013) Mycobacterium tuberculosis Specific CD8+ T Cells Rapidly Decline with Antituberculosis Treatment. PLoS ONE 8(12): e81564. doi:10.1371/journal.pone.0081564en_US
dc.identifier.other10.1371/journal.pone.0081564
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1653
dc.description.abstractBiomarkers associated with response to therapy in tuberculosis could have broad clinical utility. We postulated that the frequency of Mycobacterium tuberculosis (Mtb) specific CD8+ T cells, by virtue of detecting intracellular infection, could be a surrogate marker of response to therapy and would decrease during effective antituberculosis treatment. Objectives: We sought to determine the relationship of Mtb specific CD4+ T cells and CD8+ T cells with duration of antituberculosis treatment. Materials and Methods: We performed a prospective cohort study, enrolling between June 2008 and August 2010, of HIV uninfected Ugandan adults (n = 50) with acid-fast bacillus smear-positive, culture confirmed pulmonary TB at the onset of antituberculosis treatment and the Mtb specific CD4+ and CD8+ T cell responses to ESAT-6 and CFP-10 were measured by IFN-c ELISPOT at enrollment, week 8 and 24. Results: There was a significant difference in the Mtb specific CD8+ T response, but not the CD4+ T cell response, over 24 weeks of antituberculosis treatment (p,0.0001), with an early difference observed at 8 weeks of therapy (p = 0.023). At 24 weeks, the estimated Mtb specific CD8+ T cell response decreased by 58%. In contrast, there was no significant difference in the Mtb specific CD4+ T cell during the treatment. The Mtb specific CD4+ T cell response, but not the CD8+ response, was negatively impacted by the body mass index. Conclusions: Our data provide evidence that the Mtb specific CD8+ T cell response declines with antituberculosis treatment and could be a surrogate marker of response to therapy. Additional research is needed to determine if the Mtb specific CD8+ T cell response can detect early treatment failure, relapse, or to predict disease progression.en_US
dc.language.isoenen_US
dc.publisherPLoS ONEen_US
dc.subjectMycobacterium tuberculosisen_US
dc.subjectCD8+ T Cellsen_US
dc.subjectAntituberculosis Treatmenten_US
dc.titleMycobacterium tuberculosis Specific CD8+ T Cells Rapidly Decline with Antituberculosis Treatmenten_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record